Physician profile
Rachel Simons
NPI 1730766353
$2,065.34
in general payments reported to CMS, 2019-2025
15 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $937 · 2024: $781 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $408.07 | 2023-2025 | Repatha |
| Novo Nordisk INC | $373.71 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $261.42 | 2023 | Azure Xt Dr Mri Surescan, Hawkone |
| Novartis Pharmaceuticals Corporation | $179.77 | 2024-2025 | |
| Esperion Therapeutics, INC. | $166.96 | 2023 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.01 | 2023-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $138.79 | 2024-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $108.42 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $95.23 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $63.39 | 2024-2025 | Camzyos |
| Pfizer INC. | $47.94 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $24.36 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.35 | 2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $15.20 | 2024 | Xarelto |
| Amarin Pharma, INC. | $13.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.